Cue Biopharma is trading 11.21% up at $31.44, with no reliable company-specific announcement or overnight catalyst identified for the September 22 rebound.
- It fell 23.70% to $28.27 on September 21, 2026.
- The September 20 positive CUE-221 Phase 2 announcement remains the latest confirmed company news.
- Broader markets are modestly higher, but not enough to establish a clear market-driven explanation.